GlassScriptPhysician profile
Kendall L Wise
NPI 1831252014
$1,835.68
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $529 · 2020: $181 · 2021: $388 · 2022: $291 · 2023: $447.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $447.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $446.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $542.33 | 2019-2023 | Erleada |
| Urogen Pharma, INC. | $170.87 | 2023 | Jelmyto |
| Astellas Pharma US INC | $164.13 | 2019-2023 | Myrbetriq |
| Pfizer INC. | $163.17 | 2019-2020 | |
| Neotract INC. | $155.98 | 2019 | |
| Myriad Genetic Laboratories, INC. | $139.47 | 2021 | |
| Endo Pharmaceuticals INC. | $132.84 | 2019-2022 | |
| Procept Biorobotics Corporation | $125.82 | 2022 | |
| Coloplast Corp | $68.51 | 2022-2023 | Speedicath |
| Tolmar Pharmaceuticals, INC. | $63.43 | 2019-2022 | |
| Dendreon Pharmaceuticals LLC | $20.99 | 2022 | |
| Urovant Sciences INC | $20.96 | 2022 | |
| Antares Pharma, INC. | $19.40 | 2022 | |
| Sumitomo Pharma America, INC. | $18.73 | 2023 | Gemtesa |
| Angiodynamics, INC. | $15.63 | 2022 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axonics, INC. | $13.42 | 2023 | Axonics |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kendall Wise listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.